About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 72808 record(s)
Req # A-2023-000967
Adverse Drug Reaction (ADR) for Brexpiprazole and Aripiprazole. Report number: E2B_06583411. ADRs for Aripiprazole. Report numbers: 001052234, E2B_06560979, E2B_06562992, E2B_06584846. ADR for Inqovi. Report number: 001052515.Organization: Health Canada
January 2024
Req # A-2023-000977
Adverse Drug Reactions (ADRs). Report numbers: 001052306, 001036664.Organization: Health Canada
January 2024
Req # A-2023-001010
Adverse Drug Reactions (ADRs). Report numbers: E2B_05752442, E2B_05348694, E2B_05752729, E2B_06197292, E2B_05293387, E2B_06255961, E2B_05853866, E2B_06181787, 001033260, 001009763.Organization: Health Canada
January 2024
Req # A-2023-001011
Adverse Drug Reactions (ADRs). Report numbers: E2B_05022807, E2B_06444300, E2B_06463679, 001042930, 001049481, E2B_06035561, E2B_06508009, 001038654, 001047565, 001048375.Organization: Health Canada
January 2024
Req # A-2023-001012
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-107190-568.Organization: Health Canada
January 2024
Req # A-2023-001014
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-107287-525.Organization: Health Canada
January 2024
Req # A-2023-001017
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-107682-242, Deputy Ministerial Meeting with Helium Developers Association of Canada.Organization: Health Canada
January 2024
Req # A-2023-001030
Adverse Drug Reactions (ADRs) for MORPHINE. Report numbers: 001051386, E2B_06578485, E2B_03703513, E2B_03967538, E2B_03707208, E2B_03707225, E2B_03967567. ADR for HEPARIN. Report number: 001051150. ADR for MIDAZOLAM. Report number: 001010623.Organization: Health Canada
January 2024
Req # A-2023-001032
Adverse Drug Reactions (ADRs) for PANTOPRAZOLE SODIUM. Report numbers: E2B_06587978, E2B_06541633, 001055161. ADRs for MESALAZINE. Report numbers: E2B_06586132, E2B_06580859, E2B_06574661, E2B_06589396, E2B_06568908, E2B_06565458, E2B_06538534.Organization: Health Canada
January 2024
Req # A-2023-001159
Adverse Drug Reaction (ADR). Report number: 001051430.Organization: Health Canada
January 2024